Sakura Finetek acquires Genemed, 3/16

March 2016—Sakura Finetek USA announced the acquisition of Genemed Biotechnologies' tissue-based advanced staining business for cancer detection, diagnosis, and monitoring. Genemed's liquid-based molecular testing products were not included in the acquisition and will be spun out as an independent business. Genemed's tissue-based advanced staining business will be integrated into Sakura Finetek with an immediate impact.

Sakura Finetek, 310-972-7800